Biomarker Effects of ALZ-801 in APOE4 Carriers With Early Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The study will investigate the effects of oral ALZ-801, in subjects with Early AD who have
the APOE4/4 or APOE3/4 genotype, on the biomarkers of core AD pathology. The objectives of
this study include determining the efficacy and safety/tolerability of ALZ-801. In addition,
the study will evaluate the extended PK profile over 8 hours in 16 subjects after 65 weeks of
treatment.